GGrantIndex
← Leaderboards

Robert J. Fox

Cleveland Clinic Foundation

$15,495,951
Attributed
$18,787,073
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,889,418 · 7

By mechanism

U01$12,484,125 · 1
R33$3,228,752 · 1
P20$2,102,345 · 2
R61$1,179,632 · 1
R01$1,053,700 · 1
K23$840,864 · 1

Top collaborators

Most similar at Cleveland Clinic Foundation

Same institution · by research overlap

Others in their field

Top investigators on “Image

Research focus

ImageFutureBaseClinical ResearchPerformanceAlzheimer&AposCostMagnetic Resonance ImagingMultiple SclerosisRandomizedCharacteristicsLesionMeasurementBrainBrain TissueDesignAffectNeurologicCerebral AtrophyNeuroprotectionClinical TrialsDisabilityDiagnosisDiffusion Magnetic Resonance Imaging

Grant awards (20)

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission$1,001,755
P20 · FY2025 · GM · contact PI
A Cognitive Risk Calculator and Screening tool for Primary Care Settings$1,047,904
R33 · FY2024 · AG
A Cognitive Risk Calculator and Screening tool for Primary Care Settings$1,104,404
R33 · FY2023 · AG
Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)$1,100,590
P20 · FY2022 · AG · contact PI
A Cognitive Risk Calculator and Screening tool for Primary Care Settings$1,076,444
R33 · FY2022 · AG
A Cognitive Risk Calculator and Screening tool for Primary Care Settings$615,414
R61 · FY2021 · AG
A Cognitive Risk Calculator and Screening tool for Primary Care Settings$564,218
R61 · FY2020 · AG
Characterization and Quantification of Myelin in the Central Nervous System$525,568
R01 · FY2020 · EB
Characterization and Quantification of Myelin in the Central Nervous System$528,132
R01 · FY2019 · EB
Ibudilast Phase II trial in progressive MS$284,857
U01 · FY2017 · NS · contact PI
Ibudilast Phase II trial in progressive MS$2,308,268
U01 · FY2016 · NS · contact PI
Ibudilast Phase II trial in progressive MS$2,827,318
U01 · FY2015 · NS · contact PI
Ibudilast Phase II trial in progressive MS$3,376,514
U01 · FY2014 · NS · contact PI
Ibudilast Phase II trial in progressive MS$585,071
U01 · FY2014 · NS · contact PI
Ibudilast Phase II trial in progressive MS$3,102,097
U01 · FY2013 · NS · contact PI
Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis$169,503
K23 · FY2008 · NS · contact PI
Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis$168,813
K23 · FY2007 · NS · contact PI
Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis$168,142
K23 · FY2006 · NS · contact PI
Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis$167,492
K23 · FY2005 · NS
Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis$166,914
K23 · FY2004 · NS